Pub 1
Pub 1
Pub 1
Complications
Introduction
Peripheral vascular diseases (PVD) present a significant health concern among individuals
diagnosed with type 2 diabetes mellitus (T2DM). The coexistence of T2DM and PVD
significantly exacerbates health risks, leading to severe complications and poorer prognoses.
Understanding the causes and complications of PVD in T2DM patients is crucial for effective
management and prevention strategies. This article delves into the multifactorial etiology of
PVD in T2DM and explores the complications that arise from this comorbidity.
313
2024, IRJEdT Volume: 06, Issue: 04 | April-2024
adipokines, promoting a chronic inflammatory state conducive to atherosclerosis and
endothelial dysfunction.
5. Smoking: Tobacco smoking is a modifiable risk factor that significantly amplifies the
risk of PVD in T2DM patients. Smoking promotes vasoconstriction, oxidative stress,
and endothelial damage, accelerating the progression of atherosclerosis and PAD.
6. Genetic Predisposition: Certain genetic factors predispose individuals to both T2DM
and PVD. Genetic variations affecting lipid metabolism, vascular function, and
inflammation pathways increase susceptibility to these conditions.
314
2024, IRJEdT Volume: 06, Issue: 04 | April-2024
synergistic effects of diabetes and PVD on cardiovascular mortality emphasize the
need for aggressive risk factor modification and timely interventions.
Conclusion
Peripheral vascular diseases pose formidable challenges in the management of type 2 diabetes
mellitus. The intricate interplay of metabolic, vascular, and lifestyle factors contributes to the
development and progression of PVD in diabetic individuals. Recognizing the causes and
complications of PVD in T2DM patients is paramount for implementing targeted preventive
measures, optimizing glycemic and cardiovascular control, and mitigating adverse outcomes.
Multidisciplinary approaches encompassing lifestyle modifications, pharmacotherapy,
revascularization procedures, and wound care are essential components of comprehensive
management strategies aimed at preserving limb function and enhancing the overall well-
being of diabetic individuals with peripheral vascular diseases.
Reference
1. Cost-effective management of diabetes mellitus. Motala AA, Pirie FJ, Rauff S, Bacus HB.
https://pubmed.ncbi.nlm.nih.gov/16774016/ Ethn Dis. 2006;16:0–84.
3. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and
2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Saeedi P,
Petersohn I, Salpea P, et al. Diabetes Res Clin Pract. 2019;157:107843.
315
2024, IRJEdT Volume: 06, Issue: 04 | April-2024
7. Update on peripheral artery disease: epidemiology and evidence-based facts. Shu J,
Santulli G. Atherosclerosis. 2018;275:379–381.
8. Peripheral arterial disease in women: an overview of risk factor profile, clinical features,
and outcomes. Jelani QU, Petrov M, Martinez SC, Holmvang L, Al-Shaibi K, Alasnag M.
https://link.springer.com/article/10.1007/s11883-018-0742-x. Curr Atheroscler Rep.
2018;20:40.
9. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. Hiatt WR, Fowkes
FG, Heizer G, et al. N Engl J Med. 2017;376:32–40. [PubMed] [Google Scholar]
10. Risk factors of peripheral arterial disease: a case control study in Sri Lanka. Weragoda J,
Seneviratne R, Weerasinghe MC, Wijeyaratne SM.
https://link.springer.com/article/10.1186/s13104-016-2314-x. BMC Res Notes. 2016;9:508.
14. Vascular disease in the lower limb in type 1 diabetes. Edmonds M. Cardiovasc Endocrinol
Metab. 2019;8:39–46.
15. Peripheral vascular disease risk in diabetic individuals without coronary heart disease.
Wilcox T, Newman JD, Maldonado TS, Rockman C, Berger JS. Atherosclerosis.
2018;275:419–425.
16. Peripheral vascular diseases; noninvasive approach for evaluation and treatment. Malik
GA, Qureshi KK, Ahmad I. Professional Med J. 2007;14:134–143
316
2024, IRJEdT Volume: 06, Issue: 04 | April-2024